Compare AOUT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AOUT | ENGN |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 115.9M |
| IPO Year | 2020 | N/A |
| Metric | AOUT | ENGN |
|---|---|---|
| Price | $9.76 | $1.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $12.50 | ★ $21.08 |
| AVG Volume (30 Days) | 32.1K | ★ 3.6M |
| Earning Date | 03-12-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $222,322,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.55 | N/A |
| 52 Week Low | $6.26 | $1.40 |
| 52 Week High | $13.46 | $12.25 |
| Indicator | AOUT | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 29.13 |
| Support Level | $8.09 | $1.40 |
| Resistance Level | $9.84 | $1.87 |
| Average True Range (ATR) | 0.50 | 0.11 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 63.24 | 37.84 |
American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.